Denali Therapeutics Inc (NASDAQ:DNLI) – Stock analysts at Cantor Fitzgerald boosted their FY2019 earnings per share (EPS) estimates for shares of Denali Therapeutics in a note issued to investors on Sunday, March 17th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will earn ($1.82) per share for the year, up from their previous forecast of ($2.03). Cantor Fitzgerald currently has a “Neutral” rating and a $25.00 target price on the stock.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Tuesday, March 12th. The company reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.90. The business had revenue of $125.68 million during the quarter, compared to analyst estimates of $9.73 million. Denali Therapeutics had a negative net margin of 28.06% and a negative return on equity of 7.12%.

A number of other brokerages have also weighed in on DNLI. ValuEngine lowered shares of Denali Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Zacks Investment Research lowered shares of Denali Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, March 12th.

Shares of Denali Therapeutics stock opened at $21.86 on Wednesday. The company has a market capitalization of $2.33 billion, a P/E ratio of -56.05 and a beta of 2.11. Denali Therapeutics has a fifty-two week low of $12.32 and a fifty-two week high of $25.05.

In related news, COO Alexander O. Schuth sold 7,500 shares of the firm’s stock in a transaction that occurred on Friday, January 11th. The shares were sold at an average price of $20.37, for a total value of $152,775.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Ryan J. Watts sold 18,334 shares of the firm’s stock in a transaction that occurred on Tuesday, February 5th. The shares were sold at an average price of $18.72, for a total transaction of $343,212.48. The disclosure for this sale can be found here. In the last three months, insiders sold 78,500 shares of company stock valued at $1,596,284. 21.30% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the business. Quantamental Technologies LLC bought a new position in Denali Therapeutics in the fourth quarter valued at approximately $41,000. Great West Life Assurance Co. Can bought a new position in Denali Therapeutics in the third quarter valued at approximately $161,000. Legal & General Group Plc boosted its stake in Denali Therapeutics by 16.3% in the fourth quarter. Legal & General Group Plc now owns 8,638 shares of the company’s stock valued at $179,000 after acquiring an additional 1,212 shares during the last quarter. Essex Investment Management Co. LLC bought a new position in Denali Therapeutics in the fourth quarter valued at approximately $182,000. Finally, Amundi Pioneer Asset Management Inc. bought a new position in Denali Therapeutics in the fourth quarter valued at approximately $194,000. 71.47% of the stock is currently owned by hedge funds and other institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Read More: Insider Trading – What You Need to Know

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.